文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

澳大利亚硫嘌呤使用者TPMT检测利用及相关因素:全国回顾性数据链接研究

Utilization and associated factors of TPMT testing among Australian adults receiving thiopurines: A national retrospective data-linkage study.
PubMed 文献 · Pharmacotherapy · 2024-11-26

该研究利用澳大利亚PBS、MBS和2021年人口普查数据,纳入2020至2022年62,574例≥18岁硫嘌呤使用者,评估TPMT检测率及相关因素。结果显示32.5%接受了TPMT检测,专科医生处方、非英语家庭语言、无慢性病、无需核心活动协助及高教育程度与检测几率较高相关,偏远地区居民检测几率显著较低。

要点

  • 澳大利亚硫嘌呤使用者中仅32.5%接受了TPMT检测。
  • 专科医生处方者TPMT检测几率是仅初级保健医生处方者的2.12倍。
  • 偏远地区居民检测几率显著低于大城市居民(aOR 0.49)。

核心结论

  • 澳大利亚硫嘌呤使用者中TPMT检测利用率低,需针对性干预以解决差异并提高检测率。

研究设计与样本

  • 回顾性队列研究,利用PBS、MBS和2021年人口普查行政数据,通过ABS DataLab的PLIDA访问。
  • 纳入2020至2022年62,574例≥18岁流行硫嘌呤使用者,采用多因素logistic回归分析TPMT检测相关因素。

主要发现

  • 62,574例使用者中20,327例(32.5%)接受了TPMT检测(2011-2022年)。
  • 至少一种硫嘌呤由专科医生处方者较仅由初级保健医生处方者检测几率更高(aOR 2.12,95%CI 2.02-2.22)。
  • 非英语家庭语言(aOR 1.29,95%CI 1.22-1.36)、无慢性健康问题(aOR 1.18,95%CI 1.13-1.24)、无需核心活动协助(aOR 1.16,95%CI 1.08-1.23)、较高教育程度(aOR 1.11,95%CI 1.06-1.11)与检测几率较高相关。
  • 偏远地区居民较大城市居民检测几率显著更低(aOR 0.49,95%CI 0.39-0.60)。

临床怎么用

  • 临床药师应关注硫嘌呤使用者TPMT检测率低的问题,尤其初级保健医生处方及偏远地区患者。
  • 建议针对处方来源和地域差异设计干预措施,促进TPMT检测以降低毒性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Thiopurine drugs are metabolized by thiopurine methyltransferase (TPMT) and low TPMT activity can result in severe adverse drug reactions. Therefore, TPMT testing is recommended for individuals receiving thiopurines to reduce the risk of toxicity. OBJECTIVES: The objectives of this study were to assess the rate of TPMT testing among individuals receiving thiopurines and explore factors associated with undergoing TPMT testing in Australia. METHODS: This retrospective cohort study utilized administrative data from the Pharmaceutical Benefits Scheme (PBS), Medicare Benefits Schedule (MBS), and the 2021 Census, accessed via the Person Level Integrated Data Asset (PLIDA) at the Australian Bureau of Statistics (ABS) DataLab. Individuals receiving thiopurines aged 18 years or above were identified using PBS data and exposure to TPMT testing was determined using MBS data. Multivariate logistic regression was performed to identify factors associated with TPMT testing. RESULTS: A total of 62,574 prevalent thiopurine users were identified between 2020 and 2022. Of these, 20,327 (32.5%) underwent TPMT testing (2011-2022). The most significant factor associated with TPMT testing was having at least one thiopurine medication prescribed by a medical specialist (adjusted odds ratio [aOR] 2.12, 95% confidence interval [CI] 2.02-2.22), compared to having medication solely prescribed by primary care physicians (PCPs). Other significant factors associated with TPMT testing included speaking a non-English language at home (aOR 1.29, 95% CI 1.22-1.36), having no chronic health conditions (aOR 1.18, 95% CI 1.13-1.24), not requiring assistance with core activities (aOR 1.16, 95% CI 1.08-1.23), and having a higher educational attainment (aOR 1.11, 95% CI 1.06-1.11). Compared to living in major cities, individuals living in remote areas were significantly less likely to undergo testing (aOR 0.49, 95% CI 0.39-0.60). CONCLUSION: Our study highlights the low utilization of TPMT testing in Australia and suggests the need for targeted interventions to address disparities and improve TPMT testing.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Yiu CH, Ianni BD, Fujita K, et al. Utilization and associated factors of TPMT testing among Australian adults receiving thiopurines: A national retrospective data-linkage study. Pharmacotherapy. 2024. PMID: 39587965. doi:10.1002/phar.4631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。